Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 7:27 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 64 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Diabetes Mellitus, Type 2
Interventions
LY2189265 and Lifestyle Measures, Placebo solution and Lifestyle Measures
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
12
States / cities
Concord, California • Lancaster, California • Mission Hills, California + 9 more
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

GLP_1 RA Ultrasound Study

NCT06581120
Conditions
Glucagon Like Peptide-1 (GLP-1, Delayed Gastric Emptying, Risk of Aspiration, Diabetes, Morbid Obesity
Interventions
Glucagon-Like Peptide-1 receptor agonists, Point of Care Gastric Ultrasound
Drug · Diagnostic Test
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
10 Years to 25 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Cincinnati, Ohio
Conditions
Healthy, Type 2 Diabetes Mellitus (T2DM)
Interventions
Tirzepatide, Placebo, Dulaglutide
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
21 Years to 70 Years
Enrollment
142 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
South Miami, Florida
Conditions
Diabetes Mellitus, Type 2
Interventions
Dulaglutide Pen, Semaglutide Pen
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
14
States / cities
Fresno, California • Long Beach, California • Palm Harbor, Florida + 10 more
Conditions
Type 2 Diabetes
Interventions
Tirzepatide, Dulaglutide, Semaglutide
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
40 Years and older
Enrollment
70,000 participants
Timeline
2024 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Cardiovascular Disease, Diabetes Mellitus, Type 2
Interventions
Dulaglutide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
50 Years and older
Enrollment
9,901 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
51
States / cities
Mobile, Alabama • Pell City, Alabama • Phoenix, Arizona + 48 more
Conditions
Diabetes Mellitus, Type 2
Interventions
LY3457263, Placebo, Dulaglutide
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
20 Years to 75 Years
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
5
States / cities
Anniston, Alabama • Anaheim, California • South Miami, Florida + 2 more
Conditions
Type 2 Diabetes, Chronic Kidney Disease
Interventions
Dulaglutide, Insulin glargine, Insulin lispro
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
577 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
47
States / cities
Montgomery, Alabama • Azusa, California • Granada Hills, California + 39 more
Conditions
Diabetes Mellitus, Type 2
Interventions
LY3493269, Dulaglutide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 70 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
3
States / cities
Anaheim, California • Miami, Florida • San Antonio, Texas
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Holding vs. Continuing Incretin-based Therapies Before Upper Endoscopy

NCT06533527
Conditions
Diabetes Mellitus, Type 2, Obesity, Gastroparesis
Interventions
GLP-1 medication
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
Not listed
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
2
States / cities
Weston, Florida • Cleveland, Ohio
Not yet recruiting Phase 4 Interventional Accepts healthy volunteers

Metabolic Surgery for Atrial Fibrillation Elimination

NCT07027969
Conditions
Atrial Fibrillation, Obesity and Obesity-related Medical Conditions
Interventions
Roux-en-Y Gastric Bypass or Sleeve Gastrectomy, Anti-Obesity Medication (AOM) treatment
Procedure · Drug
Lead sponsor
Ali Aminian
Other
Eligibility
18 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Diabetes Mellitus, Type 1, Endothelial Dysfunction
Interventions
Dulaglutide, Placebo
Drug
Lead sponsor
AdventHealth Translational Research Institute
Other
Eligibility
18 Years to 40 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Orlando, Florida
Conditions
Type 2 Diabetes Mellitus, Obesity, Overweight
Interventions
Semaglutide, Dulaglutide
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
120,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Boston, Massachusetts
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of the Effect of Dulaglutide on the Action of Warfarin in Healthy Participants

NCT01432938
Conditions
Diabetes Mellitus, Type 2
Interventions
dulaglutide, Warfarin
Biological · Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Dallas, Texas
Conditions
Chronic Kidney Diseases
Interventions
dulaglutide injection
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Nashville, Tennessee
Conditions
Diabetes Mellitus, Type 2
Interventions
Insulin Glargine, LY2189265, Insulin Lispro
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
884 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
36
States / cities
Concord, California • La Mesa, California • Lancaster, California + 33 more
Conditions
Type 2 Diabetes
Interventions
Tirzepatide, Dulaglutide
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
11
States / cities
Cooper City, Florida • West Palm Beach, Florida • Skokie, Illinois + 6 more
Conditions
Type 2 Diabetes
Interventions
Dulaglutide
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
10 Years to 17 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
41
States / cities
Tucson, Arizona • Little Rock, Arkansas • Los Angeles, California + 34 more
Conditions
Type 2 Diabetes Mellitus
Interventions
Placebo, Dulaglutide, Glimepiride
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
6
States / cities
Chino, California • Miami, Florida • St Louis, Missouri + 3 more
Conditions
Diabetes Mellitus, Type 2
Interventions
Dulaglutide
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,842 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
72
States / cities
Chandler, Arizona • Mesa, Arizona • Phoenix, Arizona + 67 more
Conditions
Diabetes Mellitus, Type 2
Interventions
Dulaglutide
Biological
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Daytona Beach, Florida
Conditions
Type 2 Diabetes Mellitus
Interventions
tirzepatide, Dulaglutide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
318 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
35
States / cities
Mobile, Alabama • Anaheim, California • Fresno, California + 30 more
Conditions
Type 2 Diabetes Mellitus
Interventions
Tirzepatide, Dulaglutide
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
40 Years and older
Enrollment
13,299 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
121
States / cities
Birmingham, Alabama • Concord, California • Covina, California + 106 more
Conditions
Diabetes Mellitus, Type 2
Interventions
Dulaglutide, Placebo, Insulin Glargine, Metformin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
13
States / cities
Fresno, California • San Mateo, California • Tustin, California + 10 more